UPDATE: Goldman Sachs Downgrades Cardinal Health (CAH) to Neutral
- Top 10 News for 9/26 - 9/30: Deutsche Bank Soars on Settlement; Twitter Back in the M&A Fray; Nike 'Just Didn't Do It' in Q1
- Wall Street rallies, led by Deutsche Bank, financials
- Viacom (VIAB) Forms Special Committee; Will Explore Potential Combination with CBS (CBS)
- Deutsche Bank (DB) Said Near $5.4B Settlement with U.S. - AFP
- Oil up second straight month on OPEC-fueled rally
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
(Updated - September 16, 2016 8:33 AM EDT)
Goldman Sachs downgraded Cardinal Health (NYSE: CAH) from Conviction Buy to Neutral with a price target of $83 (prior $90). Analyst Robert P. Jones sees moderating brand pricing.
Jones explained, "We remove CAH from the Americas Conviction List and downgrade it to Neutral (from Buy) as softer brand price inflation presents an additional risk to earnings in a year when EPS growth was already below CAH’s long-term (3-year) target of 10-15%. Further, a more permanent change in brand pricing could present a structural headwind to the current earnings growth model. In addition, the upside drivers of EPS that we identified in our December 2015 upgrade have not been as accretive as expected (Cordis, Medical), with CAH recently lowering guidance for Cordis accretion in FY17."
Shares of Cardinal Health closed at $76.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Reiterates Outperform on Pepsi (PEP) Following Solid 3Q
- MKM Partners Raises Price Target on BlackBerry (BBRY) Following 2Q Beat
- Jefferies Raises price Target on Worthington Industries (WOR) to $42 Following Solid 1Q
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Analyst PT Change, Downgrades
Related EntitiesGoldman Sachs Conviction Buy List, Goldman Sachs, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!